Genetic variants in toll‐like receptor 4 are associated with lack of steroid‐responsiveness in pediatric ITP patients. Issue 4 (20th January 2020)

• Record Type: Journal Article
• Authors: Kim, Taylor Olmsted; Flanagan, Jonathan M.; Habibi, Ali; Arulselvan, Abinaya; Lambert, Michele P.; Grace, Rachael F.; Despotovic, Jenny M.
• Is Part Of: American journal of hematology. Volume 95:Issue 4(2020:Apr.)
• Page Start: 395
• Page End: 400
• Publication Date: 2020-01-20
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25716
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Although the most common front‐line therapies for immune thrombocytopenia (ITP) have been in use for decades, it is still not possible to predict an individual patient's clinical course and response to therapy. Patients are managed with a trial‐and‐error approach and often suffer side effects of therapies which could have been avoided if response prediction were possible. Corticosteroids are the most frequently used upfront therapy for adults and children with ITP. Our group performed whole exome sequencing on a cohort of pediatric ITP patients, and identified two missense single nucleotide variants (SNV) in Toll‐like receptor 4 ( TLR4 ). These coding variants in TLR4 had an increased frequency in Caucasian patients with poor response to upfront steroid therapy. Both TLR4 (D299G; rs4986790) and TLR4 (T399I; rs4986791) had a minor allele frequency (MAF) of 20.7% in those patients unresponsive to steroids, but were present at lower allele frequencies of 2.3% and 3.4% in responders respectively ( P < .001). These findings were consistent with the trend identified in an independent cohort of pediatric ITP patients treated with corticosteroids who underwent direct genotyping for both SNVs. This study identified two candidate genetic variants in two unique cohorts of ITP patients which may contribute to steroid response and have prognostic implications for treatment response in ITP.